Fen Phen Health Issues
Fen Phen has been linked to many different health complications.
Initially a Fen Phen patient may have experienced shortness in breath.
Because shortness in breath can be attributed to many other things,
patients did not feel that was the direct result of taking Fen Phen.
Since Fen Phen is a diet drug, many individuals were overweight
to begin with and experienced shortness of breath on a regular basis.
In fact, the feeling of shortness in breath can be attributed to
pulmonary hypertension, a condition when there is high blood pressure
in the artery that pushes oxygen-lacking blood from the heart to
the lungs that causes shortness of breath. The two valves on the
left side of the heart, the aortic valve and the mitral valve, are
affected by Fen Phen intake, which causes regurgitation to occur,
a heart valve problem.
Fen Phen can cause cell lining within the capillaries in the lungs
to peel away, allowing blood to leak through into the muscle cells.
Constriction then occurs, putting pressure back onto the capillaries.
As time goes on, blood flow is cut off between the heart and the
lungs, which increases the pressure and expands the right side of
the heart. This can result in serious complications like heart failure
and even death when untreated.
If you have experienced any side effects due to the intake of Fen
Phen diet pills, please contact us.
Fen Phen Cover Up?
Back in 1997, studies began to show the potentially deadly effects
of Fen Phen. The FDAs key reviewer, Dr. Leo Lutwak, believed
American Home Products knew about the heart problems their diet
drug caused long before its removal from the U.S. market. Dr. Lutwak
thinks that AHP distorted his research in order to make Fen Phen
appear like there was no way to predict the valve dangers that result
from the use of the drug. Dr. Lutwak thinks that the AHPs
response to his research was part of a cover up so that they could
continue to market and sell the popular drug.
The FDA did not want Dr. Lutwak to testify so he said he was going
to retire in order to be able to. At the time, Dr. Lutwaks
testimony was very important to show that AHP did have knowledge
of the damaging effects of their drug but did not disclose this
information and properly warn the patients. The company did not
pull Fen Phen from the shelves until the FDA began their official
investigation on the heart problems linked to the drug. AHP continues
to litigate their cases aggressively to this day.